Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review
Current Oncology · 2024
DOI: 10.3390/curroncol31040134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Shamim Mortuza und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology, London Health Sciences Centre, London, ON N6A 5W9, Canada. Hauptthemen laut MEDLINE: RNA Splicing Factors, Mutation, Myelodysplastic Syndromes, World Health Organization. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Myelodysplastic neoplasms (MDS) with ring sideroblasts (RS) are diagnosed via bone marrow aspiration in the presence of either (i) ≥15% RS or (ii) 5–14% RS and an SF3B1 mutation. In the MEDALIST trial and in an interim analysis of the COMMANDS trial, lower-risk MDS-RS patients had decreased transfusion dependency with luspatercept treatment. A total of 6817 patients with suspected hematologic malignancies underwent molecular testing using a next-generation-sequencing-based genetic assay and 395 MDS patients, seen at our centre from 1 January 2018 to 31 May 2023, were reviewed. Of these, we identified 39 evaluable patients as having lower-risk MDS with SF3B1 mutations: there were 20 (51.3%) males and 19 (48.7%) females, with a median age of 77 years (range of 57 to 92). Nineteen (48.7%) patients had an isolated SF3B1 mutation with a mean variant allele frequency of 35.2% +/− 8.1%, ranging from 7.4% to 46.0%. There were 29 (74.4%) patients with ≥15% RS, 6 (15.4%) with 5 to 14% RS, one (2.6%) with 1% RS, and 3 (7.7%) with no RS. Our study suggests that a quarter of patients would be missed based on the morphologic criterion of only using RS greater than 15% and supports the revised 2022 definitions of the World Health Organization (WHO) and International Consensus Classification (ICC), which shift toward molecularly defined subtypes of MDS and appropriate testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology, London Health Sciences Centre, London, ON N6A 5W9, Canada.
- Department of Medicine, Division of Hematology, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
- Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada.
- Edmonton Base Lab, Alberta Precision Laboratories, Edmonton, AB T2N 1M7, Canada.
ORCID-Profile: Shamim Mortuza, Benjamin Chin-Yee, Jonathan Keow, Cyrus C Hsia
Zitieren
APA
Mortuza, S., Chin-Yee, B., James, T. E., Chin-Yee, I. H., Hedley, B. D., Ho, J. M., Saini, L., Lazo-Langner, A., Schenkel, L., Bhai, P., Sadikovic, B., Keow, J., Sangle, N., & Hsia, C. C. (2024). Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review. Current Oncology. https://doi.org/10.3390/curroncol31040134
Vancouver
Mortuza S, Chin-Yee B, James TE, Chin-Yee IH, Hedley BD, Ho JM, et al. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review. Current Oncology. 2024. doi:10.3390/curroncol31040134
BibTeX
@article{Mortuza2024,
author = {Mortuza, Shamim and Chin-Yee, Benjamin and James, Tyler E and Chin-Yee, Ian H and Hedley, Benjamin D and Ho, Jenny M and Saini, Lalit and Lazo-Langner, Alejandro and Schenkel, Laila and Bhai, Pratibha and Sadikovic, Bekim and Keow, Jonathan and Sangle, Nikhil and Hsia, Cyrus C},
title = {Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31040134}
}
EUVIMED